BridgeBio Pharma (BBIO) closed the most recent trading day at $10.02, moving +0.1% from the previous trading session. The stock outpaced the S&P 500’s daily loss of 2.77%. Elsewhere, the Dow lost 2.82%, while the tech-heavy Nasdaq lost 0.83%.

Coming into today, shares of the rare disease drug developer had lost 6.88% in the past month. In that same time, the Medical sector lost 0.16%, while the S&P 500 lost 1.35%.

Wall Street will be looking for positivity from BridgeBio Pharma as it approaches its next earnings report date. The company is expected to report EPS of -$1.13, up 4.24% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $8.73 million, up 1796.74% from the year-ago period.

For the full year, our Zacks Consensus Estimates are projecting earnings of -$3.95 per share and revenue of $75.02 million, which would represent changes of -1.28% and +7.61%, respectively, from the prior year.

It is also important to note the recent changes to analyst estimates for BridgeBio Pharma. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company’s business outlook.

Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. BridgeBio Pharma is holding a Zacks Rank of #3 (Hold) right now.

The Medical – Generic Drugs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 178, which puts it in the bottom 30% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

You can find more information on all of these metrics, and much more, on

7 Best Stocks for the Next 30 Days

Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers “Most Likely for Early Price Pops.”

Since 1988, the full list has beaten the market more than 2X over with an average gain of +25.4% per year. So be sure to give these hand-picked 7 your immediate attention. 

See them now >>

Click to get this free report

BridgeBio Pharma, Inc. (BBIO): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Source: Nasdaq


Please enter your comment!
Please enter your name here